NCT04294251View on ClinicalTrials.gov

Efficacy and Safety of DWP450 in Subjects With Benign Masseteric Hypertrophy

PHASE3CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

March 4, 2020

Primary Completion Date

January 7, 2021

Study Completion Date

August 10, 2021

Conditions
Benign Masseteric Hypertrophy
Interventions
DRUG

DWP450

Botulinum toxin type A(DWP450) will be administered intramuscularly to the bilateral masseter muscles on Day 1.

DRUG

Placebo

Placebo(Normal Saline) will be administered intramuscularly to the bilateral masseter muscles on Day 1.

Trial Locations (1)

Unknown

Chung-ang University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

NCT04294251 - Efficacy and Safety of DWP450 in Subjects With Benign Masseteric Hypertrophy | Biotech Hunter | Biotech Hunter